Trichothiodystrophy (TTD) is a rare congenital disorder caused by genetic mutations, leading to hair and skin abnormalities. We report successful treatment of a TTD case using dupilumab, a monoclonal antibody targeting IL-4Rα. The patient, a 7-year-old boy, exhibited significant improvement in skin and hair conditions, suggesting the potential of dupilumab as a therapeutic option for TTD. Further research is needed to elucidate its mechanism and efficacy in TTD treatment.
Dupilumab treatment of trichothiodystrophy in a child / Magnaterra E.; Giovannini M.; Filippeschi C.; Pedaci F.A.; Tronconi G.; Callea M.; Ricci S.; Mori F.; Parpagnoli M.; Oranges T.. - In: PEDIATRIC DERMATOLOGY. - ISSN 0736-8046. - ELETTRONICO. - (2024), pp. 0-0. [10.1111/pde.15612]
Dupilumab treatment of trichothiodystrophy in a child
Magnaterra E.;Giovannini M.;Filippeschi C.;Pedaci F. A.;Tronconi G.;Callea M.;Ricci S.;Parpagnoli M.;Oranges T.
2024
Abstract
Trichothiodystrophy (TTD) is a rare congenital disorder caused by genetic mutations, leading to hair and skin abnormalities. We report successful treatment of a TTD case using dupilumab, a monoclonal antibody targeting IL-4Rα. The patient, a 7-year-old boy, exhibited significant improvement in skin and hair conditions, suggesting the potential of dupilumab as a therapeutic option for TTD. Further research is needed to elucidate its mechanism and efficacy in TTD treatment.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
